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Local administration of abciximab using
a ClearWay RX infusion catheter in a patient
with acute coronary syndrome caused by
late in−stent thrombosis
Lokalne podanie abciximabu przy użyciu cewnika infuzyjnego ClearWay RX
u chorego z ostrym zespołem wieńcowym spowodowanym późną zakrzepicą w stencie
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A b s t r a c t
We present a case of a 43 year-old male with a diagnosis of non-ST-segment elevation acute coronary syndrome related to
in-stent thrombosis successfully treated with intralesion administration of abciximab via a local drug delivery catheter and
thrombectomy during primary percutaneous coronary intervention.
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INTRODUCTION
The ClearWay RX Local Therapeutic Infusion Catheter (Atrium
Medical, USA) is a rapid exchange, non-dilatation catheter
with a polytetrafluoroethylene balloon used for the localised
infusion or irrigation of various diagnostic, embolic and the-
rapeutic agents into the coronary and peripheral vasculature.
We report a case of acute coronary syndrome caused by late
in-stent thrombosis successfully treated with a combination
of intralesion administration of abciximab using a ClearWay
RX infusion catheter and thrombus aspiration using a throm-
bectomy device.
CASE REPORT
The 43 year-old male patient was transferred directly from
home to our Department by ambulance with a diagnosis of
non-ST-segment elevation acute coronary syndrome. He com-
plained of crushing retrosternal chest pain of 11 hours’ dura-
tion. The initial electrocardiogram showed ST-segment de-
pression and negative T waves in II, III, aVF leads. He was
haemodynamically stable (Killip class I), with arterial blood
pressure of 130/90 mm Hg and pulse rate of 60 bpm. His risk
factors of coronary artery disease included arterial hyperten-
sion and smoking. Three months before admission, he had
suffered an acute inferior wall ST-segment elevation myocar-
dial infarction, and was successfully treated with primary per-
cutaneous coronary intervention (PCI) within the right coro-
nary artery with bare-metal stent (3.0 × 10 mm at 14 atm.)
implantation. The final outcome of index PCI was good, with
optimal epicardial flow. Typical pharmacotherapy, including
acetylsalicylic acid (75 mg once daily), clopidogrel (75 mg
once daily, for 12 months), metoprolol succinate (100 mg
daily), ramipril (10 mg once daily), and atorvastatin (40 mg
once daily), was prescribed on discharge. However, pharma-
cotherapy — including antiplatelet drugs — had been com-
pletely stopped nine days before the described event due to
unknown reasons.
During the transfer by ambulance, the patient received
300 mg of acetylsalicylic acid, 600 mg of clopidogrel and
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5,000 U of unfractionated heparin. Immediate coronary an-
giography using the femoral approach and standard 6 French
diagnostic catheters was performed showing an acute occlu-
sion of the distal right coronary artery caused by in-stent
thrombosis (Fig. 1A) and normal remaining arteries. PCI of
the infarct-related artery was attempted using a Launcher
(Medtronic Vascular, USA) 6 French Judkins right 4.0 guiding
catheter. Additional bolus of unfractionated heparin was gi-
ven to achieve an activated clotting time of 250 s. The site of
occlusion was crossed with a soft 0.014-inch BMW (Abbott
Vascular, USA) guidewire, but no improvement in the flow
was observed. Then a 10 mg bolus of abciximab was given
over 60 s using a ClearWay RX infusion catheter locally at the
place of the artery occlusion. Reduction of the thrombus load
and restoration of the distal flow was achieved (Fig. 1B). An
additional two passages of Diver C.E. (Invatec, Italy) were
performed. Aspiration success was confirmed by thrombus
fragments and debris retrieval. Optimal epicardial (TIMI gra-
de 3) flow was achieved (Fig. 1C). Due to persistent stenosis
in the distal part of the artery, an additional stent (drug-eluting
stent — Promus [Boston Scientific, USA] 3.0 × 18 mm at 18 atm.)
was implanted overlapping the distal part of the previous one
(Fig. 2A). Grayscale intravascular ultrasound was perform to check
the result of the PCI. An inadequate stent expansion of the
previously implanted stent was confirmed (Fig. 2B). Both stents
were postdilatated with a Maverick (Boston Scientific, USA)
balloon catheter 3.5 × 15 mm up to 16 atm. The final TIMI
grade 3 flow without residual stenosis was achieved (Fig. 2C).
Optimal expansion of both stents was confirmed by intrava-
scular ultrasound. After PCI, the patient was symptom-free
and peak levels of cardiac markers after PCI were: CK-MB
44 IU/L, and troponin I 1.84 µg/L. In the control echocardio-
Figure 1. Primary angioplasty in patient with ST-segment elevation myocardial infarction caused by late stent thrombosis;
A. Coronary angiography in the left anterior oblique view showing in-stent thrombosis of the distal right coronary artery;
B. Reduction of the thrombus load and restoration of the distal flow after abciximab administration at the site of the occlusion
via a local drug delivery catheter; C. Control angiogram recorded after two passages of manual aspiration catheter
Figure 2. Primary angioplasty in patient with ST-segment elevation myocardial infarction caused by late stent thrombosis;
A. Control angiogram recorded after additional stent implantation; B. An inadequate stent expansion of the previously implanted
bare-metal stent confirmed by grayscale intravascular ultrasound; C. Final result of the procedure with optimal epicardial flow
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gram a left ventricular ejection fraction of 60% with hypoki-
nesia of inferior wall was noted. The patient was discharged
home after five days. Upon discharge, his antiplatelet therapy
consisted of acetylsalicylic acid (75 mg once daily), and clo-
pidogrel (75 mg once daily, for 12 months).
DISCUSSION
The present case illustrates that the local administration of
abciximab via a local drug delivery catheter (ClearWay RX) is
feasible in patients with acute coronary syndrome caused by
in-stent thrombosis.
In most cases, glycoprotein (GP) IIb/IIIa inhibitors, inclu-
ding abciximab, are used as intravenous bolus and infusion
during primary PCI. There was a suggestion from a small stu-
dy that intracoronary administration of abciximab during pri-
mary PCI may improve reperfusion parameters and reduce
infarct size in comparison with intravenous use [1]. On the
other hand, no clinical benefit of intracoronary administration
of abciximab was confirmed in a large, randomised study [2].
In a recent meta-analysis of eight studies, intracoronary admi-
nistration of abciximab was associated with a significant im-
provement in myocardial perfusion, without significant bene-
fits in terms of mortality, reinfarction, or major bleeding com-
plications [3]. However, a significant relationship was observed
between the patient’s risk profile and mortality benefits from
intracoronary abciximab administration. Importantly, there is
no data to confirm the efficacy of intracoronary abciximab in
the treatment of in-stent thrombosis. Erden et al. [4] reported
a case of acute in-stent thrombosis successfully treated with
intracoronary administration of tirofiban.
Another possibility, as described here, is to use a dedica-
ted therapeutic perfusion catheter for intralesion infusion of
abciximab. Local administration may increase concentrations
of abciximab at the culprit lesion and in the distal vascular
bed, and allow optimisation of the diffusion of abciximab to
platelets within flow-limiting thrombi. Also the non-GP IIb/
/IIIa properties of abciximab mediated through inhibition of
the vibronectin and Mac-1 receptors may be greater at hi-
gher local concentrations. By potentiating the local anti-in-
flammatory effects of abciximab, reperfusion injury may be
minimised, resulting in greater myocardial salvage. Data from
the COCTAIL study has shown that administration of abcixi-
mab by local intracoronary infusion through the ClearWay
RX catheter can reduce thrombus burden and improve coro-
nary microcirculation [5]. In the recently reported INFUSE
AMI trial, local administration of abciximab was associated
with significant, although modest, reduction of the infarct size
assessed by cardiac magnetic resonance at 30 days after first,
anterior wall ST elevation myocardial infarction in compari-
son with no abciximab administration [6]. The greatest bene-
fit was observed when local infusion of abciximab was com-
bined with prior thrombus aspiration. However, limited data
is available regarding the utility of that approach for in-stent
thrombosis treatment.
In the present case, an occurrence of in-stent thrombo-
sis was probably triggered by termination of dual antiplatelet
therapy. On the other hand, late and very late in-stent throm-
bosis after bare-metal stent implantation is a rather rare enti-
ty, even in patients who stopped antiplatelet treatment, and
it may suggest a suboptimal result of the index procedure —
an inadequate stent expansion as presented here. If possible,
intravascular ultrasound should be performed in each case of
stent thrombosis to confirm stent apposition and expansion.
In patients after in-stent thrombosis, more potent P2Y12 in-
hibitors, i.e. prasugrel and ticagrelor, should be considered
especially in the case of clopidogrel treatment failure [7].
CONCLUSIONS
In conclusion, both intracoronary and intralesion abciximab
administration may be considered in high-risk patients. How-
ever, long-term follow-up results and additional randomised
trials are needed to confirm the clinical benefits of such an
approach.
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